indazoles has been researched along with Long QT Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callahan, T; Chan, JK; Guo, W; Moore, K; Patel, MR; Secord, AA; Zhang, ZY | 1 |
| Ball, HA; Dar, MM; Heath, EI; Infante, J; Kasubhai, S; Kleha, JF; Lewis, LD; LoRusso, P; Luu, T; Ma, B; Stephenson, J; Suttle, AB; Tan, AR | 1 |
| Addo, MF; Andrade-Gordon, P; Cheung, WM; Conway, BR; Croll, D; Damiano, BP; Demarest, KT; Derian, CK; Eckardt, AJ; Emanuel, S; Hecker, LR; Li, J; Li, Q; Maryanoff, BE; McComsey, DF; Smith, CE; White, KB; Ye, H; Zhang, HC | 1 |
2 trial(s) available for indazoles and Long QT Syndrome
| Article | Year |
|---|---|
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Double-Blind Method; Electrocardiography; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Long QT Syndrome; Middle Aged; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Anti-Bacterial Agents; Aza Compounds; Blood Pressure; Confidence Intervals; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Indazoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Neoplasms; Pyrimidines; Quinolines; Sulfonamides; Young Adult | 2013 |
1 other study(ies) available for indazoles and Long QT Syndrome
| Article | Year |
|---|---|
Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthesis, biological activity, and cardiovascular safety.
Topics: Animals; Cell Line; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guinea Pigs; Humans; Indazoles; Indoles; Interleukin-8; Isoenzymes; Long QT Syndrome; Maleimides; Models, Molecular; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Kinase C; Protein Kinase C beta; Structure-Activity Relationship | 2005 |